Signaturefd LLC raised its position in shares of Celgene Corporation (NASDAQ:CELG) by 19.6% during the first quarter, Holdings Channel reports. The firm owned 5,382 shares of the biopharmaceutical company’s stock after buying an additional 881 shares during the period. Signaturefd LLC’s holdings in Celgene Corporation were worth $670,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in the stock. Motco raised its stake in Celgene Corporation by 306.9% in the first quarter. Motco now owns 822 shares of the biopharmaceutical company’s stock worth $102,000 after buying an additional 620 shares during the period. Harel Insurance Investments & Financial Services Ltd. acquired a new stake in Celgene Corporation during the first quarter worth about $118,000. Carroll Financial Associates Inc. raised its stake in Celgene Corporation by 70.9% in the first quarter. Carroll Financial Associates Inc. now owns 964 shares of the biopharmaceutical company’s stock worth $119,000 after buying an additional 400 shares during the period. Oakworth Capital Inc. raised its stake in Celgene Corporation by 60.9% in the first quarter. Oakworth Capital Inc. now owns 1,089 shares of the biopharmaceutical company’s stock worth $136,000 after buying an additional 412 shares during the period. Finally, Mitsubishi UFJ Securities Holdings Co. Ltd. raised its stake in Celgene Corporation by 47.5% in the first quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,180 shares of the biopharmaceutical company’s stock worth $147,000 after buying an additional 380 shares during the period. 78.41% of the stock is currently owned by hedge funds and other institutional investors.

Celgene Corporation (CELG) traded up 0.18% during midday trading on Friday, hitting $130.61. The stock had a trading volume of 2,735,623 shares. Celgene Corporation has a 1-year low of $96.93 and a 1-year high of $139.00. The company has a 50-day moving average of $134.14 and a 200-day moving average of $124.30. The stock has a market cap of $102.18 billion, a price-to-earnings ratio of 40.45 and a beta of 1.89.

Celgene Corporation (NASDAQ:CELG) last posted its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.61 by $0.21. The business had revenue of $3.27 billion during the quarter, compared to the consensus estimate of $3.23 billion. Celgene Corporation had a return on equity of 68.51% and a net margin of 21.35%. Celgene Corporation’s quarterly revenue was up 18.7% on a year-over-year basis. During the same period in the prior year, the business posted $1.44 earnings per share. Equities research analysts forecast that Celgene Corporation will post $7.32 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This report was first reported by Daily Political and is owned by of Daily Political. If you are reading this report on another site, it was copied illegally and reposted in violation of United States & international trademark & copyright laws. The correct version of this report can be viewed at https://www.dailypolitical.com/2017/08/12/celgene-corporation-celg-shares-bought-by-signaturefd-llc.html.

A number of brokerages have commented on CELG. Cantor Fitzgerald set a $159.00 price objective on Celgene Corporation and gave the stock a “buy” rating in a research report on Thursday, April 27th. Oppenheimer Holdings, Inc. reiterated an “outperform” rating and issued a $175.00 price objective (up previously from $148.00) on shares of Celgene Corporation in a research report on Monday, July 31st. BMO Capital Markets reiterated an “outperform” rating and issued a $160.00 price objective (up previously from $152.00) on shares of Celgene Corporation in a research report on Friday, July 28th. Canaccord Genuity set a $156.00 price objective on Celgene Corporation and gave the stock a “buy” rating in a research report on Tuesday, June 6th. Finally, BidaskClub upgraded Celgene Corporation from a “sell” rating to a “hold” rating in a research report on Wednesday, June 21st. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, twenty-two have assigned a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $147.00.

In other Celgene Corporation news, insider Robert J. Hugin sold 175,970 shares of the stock in a transaction dated Thursday, June 22nd. The stock was sold at an average price of $134.14, for a total transaction of $23,604,615.80. Following the completion of the sale, the insider now directly owns 1,033,909 shares in the company, valued at approximately $138,688,553.26. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Rupert Vessey sold 4,785 shares of the stock in a transaction dated Thursday, June 15th. The stock was sold at an average price of $120.18, for a total value of $575,061.30. Following the sale, the insider now owns 4,004 shares of the company’s stock, valued at $481,200.72. The disclosure for this sale can be found here. Insiders sold 235,255 shares of company stock valued at $31,377,042 over the last 90 days. 0.95% of the stock is currently owned by company insiders.

Celgene Corporation Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.